Patents by Inventor Sarvajit Chakravarty

Sarvajit Chakravarty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190248774
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 15, 2019
    Inventors: Son Minh PHAM, Sarvajit CHAKRAVARTY, Jayakanth KANKANALA, Brahmam PUJALA, Amit SHETE, Bhawana BHATT, Anil Kumar AGARWAL, Sanjeev SONI, Jiyun CHEN
  • Publication number: 20190177310
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 13, 2019
    Inventors: Sebastian BERNALES, Luz Marina DELGADO OYARZO, Gonzalo Esteban NÚÑEZ VASQUEZ, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Bhawana BHATT, Sarvajit CHAKRAVARTY
  • Publication number: 20190106427
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 11, 2019
    Inventors: Sarvajit Chakravarty, Son Minh PHAM, Jayakanth Kankanala, Anil Kumar AGARWAL, Brahmam PUJALA, Sanjeev SONI, Satish K. ARYA, Deepak PALVE, Ashu Gupta, Varun KUMAR
  • Publication number: 20190106436
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 11, 2019
    Inventors: Sarvajit Chakravarty, Son Minh PHAM, Jayakanth Kankanala, Anil Kumar AGARWAL, Brahmam PUJALA, Sanjeev SONI, Satish K. ARYA, Deepak PALVE, Varun KUMAR
  • Publication number: 20190023666
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: July 18, 2018
    Publication date: January 24, 2019
    Inventors: Son Minh PHAM, Jiyun CHEN, Amantullah ANSARI, Pradeep S. JADHAVAR, Varshavekumar S. PATIL, Farha KHAN, Sreekanth A. RAMACHANDRAN, Anil Kumar AGARWAL, Sarvajit CHAKRAVARTY
  • Publication number: 20190023702
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: July 18, 2018
    Publication date: January 24, 2019
    Inventors: Son Minh PHAM, Jiyun CHEN, Amantullah ANSARI, Pradeep S. JADHAVAR, Varshavekumar S. PATIL, Farha KHAN, Sreekanth A. RAMACHANDRAN, Anil Kumar AGARWAL, Sarvajit CHAKRAVARTY
  • Publication number: 20180208577
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Naveen Chaklan, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Patent number: 10030004
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: July 24, 2018
    Assignee: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Naveen Chaklan, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Patent number: 9670172
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: June 6, 2017
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Sarvajit Chakravarty, Roopa Rai, Son Minh Pham, Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Vijay Kumar Sharma
  • Publication number: 20170137410
    Abstract: Fused cycloalkyl-pyrimidine compounds that are kinase inhibitors, such as multi-kinase inhibitors, are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused cycloalkyl-pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused cycloalkyl-pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Application
    Filed: June 26, 2015
    Publication date: May 18, 2017
    Applicant: Medivation Technologies, Inc
    Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI, Anil Kumar AGARWAL
  • Publication number: 20170119907
    Abstract: This disclosure describes compositions and methods for delivering and localizing therapeutic agents to therapeutic targets. This disclosure also provides multivalent forms of cationic dyes (“cationic dye multimers”) and methods by which these compounds can be used to treat joint injuries.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 4, 2017
    Applicant: Medivation Technologies, Inc.
    Inventors: David Hung, Sarvajit Chakravarty, Roopa Rai, Sebastian Bernales, Balaji Dashrath Sathe, Gonzalo Ureta, Emma McCullagh
  • Patent number: 9580425
    Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: February 28, 2017
    Assignee: Medivation Technologies, Inc.
    Inventors: Rajendra Parasmal Jain, Sarvajit Chakravarty
  • Patent number: 9550782
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor ?2A. The compounds may also bind to and are an antagonist of the adrenergic receptor ?2B; or the compounds are not antagonists of the adrenergic receptor ?2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: January 24, 2017
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
  • Patent number: 9527854
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: December 27, 2016
    Assignee: Medivation Technologies, Inc.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
  • Patent number: 9499519
    Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: November 22, 2016
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green, Amantullah Ansari
  • Publication number: 20160326137
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Application
    Filed: December 31, 2014
    Publication date: November 10, 2016
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Naveen Chaklan, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Patent number: 9481676
    Abstract: This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1,2,3,4,5,6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 1, 2016
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: David T. Hung, Andrew Asher Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
  • Patent number: 9469641
    Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds of formula (F) are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: October 18, 2016
    Assignee: Medivation Technologies, Inc.
    Inventors: David T. Hung, Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Sundeep Dugar
  • Patent number: 9458155
    Abstract: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: October 4, 2016
    Assignee: MEDIVATION TECHNOLOGIES, INC
    Inventors: David T. Hung, Andrew A. Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
  • Publication number: 20160272645
    Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 22, 2016
    Applicant: Medivation Technologies, Inc.
    Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahmam PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE